Emerging Therapies in the Management of High-Grade Serous Ovarian Carcinoma: a Focus on PARP Inhibitors
- 22.07.2017
- Gynecologic Oncology (A Fader, Section Editor)
Erschienen in:
- Verfasst von
- Karime Kalil Machado
- Stéphanie L. Gaillard
- Erschienen in
- Current Obstetrics and Gynecology Reports | Ausgabe 3/2017
Abstract
Purpose of Review
The aims of this review are to describe key clinical trials that led to Federal Drug Administration (FDA) approval of poly(ADP-ribose) polymerase (PARP) inhibitors for ovarian cancer treatment, contextualize current indications, and to present future perspectives on the use of PARP inhibitors in this setting.
Recent Findings
Since 2014, the FDA has approved three PARP inhibitors for the treatment of relapsed ovarian cancer, initially for patients with BRCA mutations and more recently, for a broader patient population.
Summary
High-grade serous ovarian carcinomas (HGSOC) account for more than 70% of epithelial ovarian cancers. DNA repair is frequently defective in these cancers, and homologous recombination pathway defects are present in approximately 50% of cases. The inhibition of PARP enzymes is a potential synthetic lethal therapeutic strategy for cancers harboring DNA repair defects, including ovarian cancers arising in the presence of BRCA mutations or other forms of homologous recombination deficiency. PARP inhibitors are now an exciting option for the treatment of patients with advanced ovarian cancer. Herein, this topic will be further explored.
Anzeige
- Titel
- Emerging Therapies in the Management of High-Grade Serous Ovarian Carcinoma: a Focus on PARP Inhibitors
- Verfasst von
-
Karime Kalil Machado
Stéphanie L. Gaillard
- Publikationsdatum
- 22.07.2017
- Verlag
- Springer US
- Erschienen in
-
Current Obstetrics and Gynecology Reports / Ausgabe 3/2017
Elektronische ISSN: 2161-3303 - DOI
- https://doi.org/10.1007/s13669-017-0215-1
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
